Published in

Elsevier, The Lancet, 9486(366), p. 649-659

DOI: 10.1016/s0140-6736(05)67137-1

Elsevier, European Urology, 2(49), p. 412

DOI: 10.1016/j.eururo.2005.12.068

Links

Tools

Export citation

Search in Google Scholar

NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish bladder cancer study and meta-analyses

Journal article published in 2005 by Montserrat García-Closas, Alexandre R. Zlotta, Núria Malats, Debra Silverman, Mustafa Dosemeci, Manolis Kogevinas, David W. Hein, Adonina Tardón, Consol Serra, Alfredo Carrato, Reina García-Closas, Josep Lloreta, Gemma Castaño-Vinyals, Meredith Yeager, Robert Welch and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Many reported associations between common genetic polymorphisms and complex diseases have not been confirmed in subsequent studies. An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk. However, current evidence is based on meta-analyses of relatively small studies (range 23–374 cases) with some evidence of publication bias and study heterogeneity. Associations between polymorphisms in other NAT and GST genes and bladder-cancer risk have been inconsistent.